Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Roche naming Colm Burke .
Filed returns
9
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Roche | Health | Reframing state expenditure on innovative pharmaceuticals as a macroeconomic investment within national health and enterprise policy. (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2026 | Roche | Economic Development and Industry | Integration of established national health and clinical research implementation frameworks into Ireland’s National Life Science Strategy (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Roche | Economic Development and Industry | Quantitative target-setting and governance structures for Ireland’s National Life Science Strategy. (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2025 | Roche | Economic Development and Industry | The development of a National Life Science Strategy should embrace international best practices through a coordinated, cross-departmental approach (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2025 | Roche | Health | Reform of national pricing and reimbursement systems for new medicines and sustainable increased investment in innovative medicines (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Roche | Health | Patient access to new medicines (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2022 | Roche | Health | Access to orphan medicinal products (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Roche | Health | Access to medicines and health data infrastructure (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Roche | Health | Drug Reimbursement (Public policy or programme) | 24 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 6 | 66.7% | |
| Economic Development and Industry | 3 | 33.3% |